Biopharma | November 14, 2025
Transition Bio and Voyager Therapeutics forge strategic collaboration to target ALS, FTD
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible
Automated parallel capillary electrophoresis system simplifies protein analysis
The company has raised US$4.5 million in funding for its AI operating system
Support for bioprocess, cell and gene therapy, and industry 4.0 initiatives
This partnership is in line with the strategic focus of DKSH Business Unit Technology to solidify its position as a leading integrated solutions provider for the scientific Instrumentation market
Subscribe To Our Newsletter & Stay Updated
